m-Doxazosin

Pajjiż: New Zealand

Lingwa: Ingliż

Sors: Medsafe (Medicines Safety Authority)

Ingredjent attiv:

Doxazosin mesilate 4.852mg equivalent to doxazosin 4 mg

Disponibbli minn:

Multichem NZ Limited

INN (Isem Internazzjonali):

Doxazosin mesilate 4.852 mg (equivalent to doxazosin 4 mg)

Dożaġġ:

4 mg

Għamla farmaċewtika:

Tablet

Kompożizzjoni:

Active: Doxazosin mesilate 4.852mg equivalent to doxazosin 4 mg Excipient: Colloidal silicon dioxide Lactose monohydrate Magnesium stearate Microcrystalline cellulose Sodium laurilsulfate Sodium starch glycolate

Unitajiet fil-pakkett:

Blister pack, PVC/PVDC/Al, 28 tablet pack., 28 tablets

Klassi:

Prescription

Tip ta 'preskrizzjoni:

Prescription

Manifatturat minn:

Excella GmbH & Co KG

Sommarju tal-prodott:

Package - Contents - Shelf Life: Blister pack, PVC/PVDC/Al, 28 tablet pack. - 28 tablets - 36 months from date of manufacture stored at or below 25°C - Blister pack, PVC/PVDC/Al, 10 blister trays of 14 tablets (140 tablet pack) - 140 tablets - 36 months from date of manufacture stored at or below 25°C

Data ta 'l-awtorizzazzjoni:

2002-06-28

Karatteristiċi tal-prodott

NEW ZEALAND DATA SHEET  
M-DOXAZOSIN 

M-DOXAZOSIN 1 MG, 2 MG AND 4 MG TABLETS 
Doxazosin Mesylate equivalent to Doxazosin 1 mg, 2 mg & 4
mg Tablets  
PRESENTATION  
m-Doxazosin 1 mg is white to off-white, round, biconvex tablet,
scored on one side.  
m-Doxazosin 2 mg is white to off-white, capsule-shaped, biconvex
tablet, scored on one side.  
m-Doxazosin 4 mg is white to off-white, capsule-shaped,
biconvex tablet, scored on both sides 
and marked “D4” on one side.  
USES  
_ACTIONS _ 
Doxazosin is a quinazoline derivative. It
exerts its vasodilator effect via selective and competitive 
blockade of post-junctional alpha-1-adrenoceptors.  

Administration of doxazosin results in a reduction of blood
pressure as a result of a reduction in 
the systemic vascular resistance. This effect is thought to result
from the selective blockade of 
the alpha-1-adrenoceptors located in the vasculature. With once
daily dosing, there is a 
significant reduction in blood pressure, which is present
throughout the day and at 24 hours post 
dose. Maximum reductions in blood pressure usually occur 2-6 hours
after dosing and are 
associated with a small increase in standing heart rate. Doxazosin
treatment in hypertensive 
patients showed similar blood pressures in the supine and
standing positions. Unlike non-
selective alpha adrenoceptor blocking agents the tolerance of
doxazosin treatment for long term 
therapy has not been established. Elevations of plasma
renin activity and tachycardia were seen 
infrequently in sustained therapy.  

Doxazosin produces favourable effects on blood lipids, with
significant increase in the HDL/total 
cholesterol ratio and tends to a favourable reduction
in total triglycerides. Doxazosin therefore 
has advantages over other diuretic and beta adrenoceptor blocking
agents, which adversely 
affect these parameters. Based on established association
of hypertension and bl